Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy

Table 2

Results of univariate analysis for locoregional recurrence and disease-free survival.

Variable	LRR		DFS
	HR (95% CI)	value	HR (95% CI)	value
Age (years)		0.965		0.173
<50	1 (ref)		1 (ref)
≥50	0.988 (0.589–1.659)		1.243 (0.909–1.698)
Tumour size, cm		0.01		≤0.001
<4	1 (ref)		1 (ref)
≥r	2.355 (1.404–3.952)		1.758 (1.286–2.403)
Tumour grade		0.015		0.488
G1-G2	1 (ref)		1 (ref)
G3	2.377 (1.182–4.778)		1.203 (0.713–2.031）
Histological type		0.806		0.035
Ductal	1 (ref)		1 (ref)
Tubular	1.097 (0.0396–3.039)		1.132 (0.613–2.089）
Others	0.692 (0.216–2.217)		0.302 (0.112–0.814）
LVI		0.093		≤0.001
Yes	1 (ref)		1 (ref)
No	0.557 (0.282–1.103)		0.486 (0.327–0.723）
Clinical N stage		0.461		0.007
N0	1 (ref)		1 (ref)
N1	1.401 (0.733–2.676)		1.979 (1.292–3.031）
N2	0.97 (0.382–2.465)		1.624 (0.937–2.812）
Clinical TNM stage		0.044		0.002
Stage II	1 (ref)		1 (ref)
Stage III	1.718 (1.015–2.907)		1.651 (1.205–2.260）
ER status		0.405		0.901
ER+	1 (ref)		1 (ref)
ER−	1.249 (0.743–2.101)		1.020 (0.746–1.395）
PR status		0.002		0.033
PR+	1 (ref)		1 (ref)
PR−	2.428 (1.379–4.276)		1.400 (1.027–1.909）
HER-2 status		0.483		0.094
HER-2 positive	1 (ref)		1 (ref)
HER-2 negative	0.797 (0.424–1.500)		0.726 (0.499–1.056）
TNBC		0.017		0.006
TNBC	1 (ref)		1 (ref)
No TNBC	0.485 (0.268–0.878)		0.592 (0.405–0.863)
Clinical tumour response		0.012		0.273
CR + PR	1 (ref)		1 (ref)
SD + PD	2.126 (1.180–3.831)		1.255 (0.836–1.886）
Pathological response		0.162		0.010
pCR	1 (ref)		1 (ref)
No pCR	4.099 (0.567–29.615)		6.262 (1.553–25.256）
Pathological N stage		≤0.001		≤0.001
N0	1 (ref)		1 (ref)
N1	1.712 (0.79–3.711)		1.753 (1.085–2.832）
N2	2.547 (1.166–5.565)		3.554 (2.231–5.662）
N3	5.644 (2.472–12.882)		7.249 (4.371–12.022）
PMRT		0.013		0.993
RT	1 (ref)		1 (ref)
No RT	1.935 (1.147–3.266）		0.999 (0.708–1.407）
Anti-HER-2 therapy		0.629		0.983
Yes	1 (ref)		1 (ref)
	0.751 (0.235–2.401）		1.007 (0.546–1.856）
Adjuvant chemotherapy		0.184		0.524
Yes	1 (ref)		1 (ref)
No	1.238 (0.903–1.695）		1.083 (0.847–1.384）
Endocrinotherapy		0.218		0.121
Yes	1 (ref)		1 (ref)
No	1.119 (0.935–1.339）		1.093 (0.977–1.223）

LRR, locoregional recurrence rates; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor; TNBC, triple-negative breast cancer; pCR, pathological complete response; CR, complete response; PR, partial response; SD, stable disease; PD, progress disease.